Could cause temporary or reversible harm; serious harm is unlikely.
Lack of Assurance of Sterility: environmental monitoring failure.
| Brand name | ARFORMOTEROL TARTRATE |
| Generic name | ARFORMOTEROL TARTRATE |
| Active ingredient(s) | ARFORMOTEROL TARTRATE |
| Distributed by / for | Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059 |
| NDC | 69097-168-48 |
| Full product label | Arformoterol Tartrate Inhalation Solution, 15 mcg/2mL, 2 mL Sterile Unit-Dose Vial packaged in 5 x 2 mL Sterile Unit-Dose Vials per pouch, NDC 69097-168-48; 60 (12 x 5) x 2 mL Sterile Unit-Dose Vials per carton, NDC 69097-168-64, Rx Only, Manufactured by: Cipla Ltd., Indore SEZ, Pithampur, India; Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. |
| Recalling firm | CIPLA |
| Distribution | Product was distributed nationwide to distributors/wholesalers who may have further distributed the product. |
| Quantity | 9041 cartons |
| Recall initiated | 2022-09-29 |
| Report date | 2022-10-12 |
| Recall completed | 2023-07-25 |
| Recall number | D-1550-2022 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Warren NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗